



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_466_24

You asked:

I would be grateful if you could tell me how many patients were treated by individual drugs from the dermatology, gastroenterology, and rheumatology departments (for any disease) for the three-month period specified within the question.

I have provided a grid of drug names and department names requested in appendix A (below). Please fill in the grid with the numbers of patients (or forward in a format that best suits you) and include data for all hospitals in the organisation (question 1).

Q1a – How many patients were treated with the following drugs from a the following departments (for any disease) from the start of Apr 2024 to the end of Jun 2024?

Please use the latest available 3 months if April to June is not available and specify which 3 months has been used.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab			
Apremilast			
Bimekizumab			
Brodalumab			
Certolizumab Pegol			
Deucravacitinib			
Etanercept			
Guselkumab			
Infliximab (Remicade)			
Infliximab (Biosimilars)			
Ixekizumab			
Risankizumab			
Secukinumab			
Tildrakizumab			
Ustekinumab			
Upadacitinib			
Vedolizumab			
Filgotinib			
Golimumab			
Mirikizumab			
Ozanimod			
Etrasimod			
Tofacitinib			
Baricitinib			
Rituximab			
Sarilumab			
Tocilizumab			

Q1b – How many patients were treated with Ustekinumab and its biosimilars from the following departments (for any disease) from the start of Jun 2024 to the end of Aug 2024?

Please use the latest available 3 months if June to August is not available and specify which 3 months has been used.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Ustekinumab (Stelara)			
Ustekinumab (Pyzchiva)			
Ustekinumab (Uzpruvo)			
Ustekinumab (Wezenla)			

Our response:

Please find below as requested tables populated with the information Medicines Management are able to provide at this current time. In relation to Q1a the period the data relates to is 1st April 24 to 30th June 24 and for Q1b 1st June 24 to 31st August 24 as requested.

Q1a - 1st April 24 to 30th June 24

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab	54	203	460
Apremilast	9	0	**
Bimekizumab	19	0	6
Brodalumab	**	0	0
Certolizumab Pegol	**	**	55
Deucravacitinib	9	0	0
Etanercept	0	0	281
Guselkumab	36	0	**
Infliximab (Remicade)	0	**	0
Infliximab (Biosimilars)	**	238	21
Ixekizumab	18	0	19
Risankizumab	44	18	0
Secukinumab	9	0	96
Tildrakizumab	15	0	0
Ustekinumab	36	177	19
Upadacitinib	14	21	22
Vedolizumab	0	187	0

Filgotinib	0	0	6
Golimumab	0	0	56
Mirikizumab	0	0	0
Ozanimod	0	**	0
Etrasimod	0	0	0
Tofacitinib	0	**	9
Baricitinib	**	0	48
Rituximab	0	0	9
Sarilumab	0	0	**
Tocilizumab	0	0	84

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Q1b - 1st June 24 to 31st August 24

Drug Name	Dermatology	Gastroenterology	Rheumatology
Ustekinumab (Stelara)	36	182	16
Ustekinumab (Pyzchiva)	0	0	0
Ustekinumab (Uzpruvo)	0	0	0
Ustekinumab (Wezenla)	0	0	0